EMA Turns Down 3 Therapies Across Oncology, Transplantation

Published Date: 30 Jun 2026

Tacquell, Yartemlea, and Xervyteg failed to secure positive CHMP recommendations after EMA identified major concerns with efficacy, safety, and data interpretability.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In high-risk muscle invasive urothelial cancer, adjuvant pembrolizumab improves disease-free survival.

2.

Early Tislelizumab May Boost PFS in Esophageal Cancer

3.

Patients with head and neck cancer who cannot receive cisplatin now have new hope.

4.

Can patients receiving immunotherapy for cancer benefit from taking vitamin D supplements?

5.

How to keep your prostate healthy and lower your risk of developing serious problems


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot